» Articles » PMID: 37859441

Changes of Locomotor Activity by Dopamine D2, D3 Agonist Quinpirole in Mice Using Home-cage Monitoring System

Overview
Specialty Psychiatry
Date 2023 Oct 20
PMID 37859441
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: : As dopamine is closely linked to locomotor activities, animal studies on locomotor activities using dopaminergic agents were widely done. However, most of animal studies were performed for a short period that there is a lack of longitudinal study on the effects of dopaminergic agents on locomotor activities. This study aimed to examine the longterm effect of a dopamine D2, D3 agonist quinpirole on locomotor activities in mice using a home-cage monitoring system.

Methods: : The locomotor activities of Institute Cancer Research mice were measured by infrared motion detectors in home-cages under the 12-hour dark and 12-hour light condition for three days after the quinpirole injection. Quinpirole was injected at a concentration of 0.5 mg/kg intraperitoneally in the beginning of the dark phase. The locomotor activities before and after the quinpirole administration were compared by the Wilcoxon signed-rank test and one-way repeated measures ANOVA.

Results: : After the quinpirole administration, the 24-hour total locomotor activity did not change ( = 0.169), but activities were significantly increased in the 12-hour dark phase sum ( = 0.013) and decreased in the 12-hour light phase sum ( = 0.009). Significant increases in the activities were observed in the dark-light difference ( = 0.005) and dark-light ratio ( = 0.005) as well.

Conclusion: : This study suggests that quinpirole injection entrains the circadian rest-activity rhythm of locomotor activities. Therefore, quinpirole can be a drug that mediates locomotor activity as a dopamine agonist as well as a modulator of the circadian rhythms.

Citing Articles

Ultradian Rest-activity Rhythms Induced by Quinpirole in Mice Using Wavelet Analysis.

Park J, Moon E, Lim H, Kim K, Suh H, Yoon M Clin Psychopharmacol Neurosci. 2024; 22(4):578-584.

PMID: 39420605 PMC: 11494435. DOI: 10.9758/cpn.23.1148.

References
1.
Whitaker N, Lindstrom T . Disposition and biotransformation of quinpirole, a new D-2 dopamine agonist antihypertensive agent, in mice, rats, dogs, and monkeys. Drug Metab Dispos. 1987; 15(1):107-13. View

2.
McDougall S, Apodaca M, Park G, Teran A, Baum T, Montejano N . MK801-induced locomotor activity in preweanling and adolescent male and female rats: role of the dopamine and serotonin systems. Psychopharmacology (Berl). 2020; 237(8):2469-2483. PMC: 7354898. DOI: 10.1007/s00213-020-05547-3. View

3.
Eilam D, Szechtman H . Biphasic effect of D-2 agonist quinpirole on locomotion and movements. Eur J Pharmacol. 1989; 161(2-3):151-7. DOI: 10.1016/0014-2999(89)90837-6. View

4.
Beaulieu J, Gainetdinov R . The physiology, signaling, and pharmacology of dopamine receptors. Pharmacol Rev. 2011; 63(1):182-217. DOI: 10.1124/pr.110.002642. View

5.
Mattingly B, Rowlett J, Lovell G . Effects of daily SKF 38393, quinpirole, and SCH 23390 treatments on locomotor activity and subsequent sensitivity to apomorphine. Psychopharmacology (Berl). 1993; 110(3):320-6. DOI: 10.1007/BF02251287. View